← Back to Search

Behavioral Intervention

Health Communication + Support for COVID-19 Vaccine Hesitancy (K-VAC Trial)

N/A
Waitlist Available
Led By Marc T. Kiviniemi, PhD
Research Sponsored by Marc Kiviniemi
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Must not have
Not within the ages of 18-99 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline and 6 months
Awards & highlights

Summary

This trial aims to see if certain strategies at the county level can help more people get the COVID-19 vaccine. They want to test if using health communication strategies alone or with additional county-specific support can

Who is the study for?
This trial is for individuals living in Appalachia who may be hesitant to receive a COVID-19 vaccine. The study aims to include diverse participants from this region to understand and address their concerns about vaccination.
What is being tested?
The study is testing if health communication alone or combined with county-specific support can increase COVID-19 vaccine uptake. It will also assess changes in perceptions and beliefs about the vaccine at the community level.
What are the potential side effects?
Since this trial focuses on communication strategies rather than medical interventions, there are no direct side effects from drugs or treatments being studied.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am either younger than 18 or older than 99 years old.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline and 6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
COVID-19 vaccination uptake
Secondary study objectives
COVID-19 Attitudes
COVID-19 Risk Perceptions
COVID-19 Vaccination Behaviors

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: Health Communication + StructuralExperimental Treatment1 Intervention
This intervention arm will include the conditions outlined and included in the health communication arm, however, they will be coupled with a series of structural and/or environmental intervention strategies as well, which are targeted to facilitate vaccine accessibility and uptake among adults in the randomly assigned study counties.
Group II: Health CommunicationExperimental Treatment1 Intervention
This intervention arm will include exclusively health communication messaging strategies that is both theory-based and community-targeted to encourage uptake of the COVID-19 vaccine delivered by trusted local communicators. Pre-identified theory-based components are attitudes, social norms, perceived behavioral control, response efficacy, and implementation intentions. The development process for the messaging will be based through a conjoint process of identification of theory- based determinants of decision-making relevant to the desired behavior change and a community-engaged process of identifying: a) community-specific messaging themes; b) trusted communicators within the target population; and c) community-specific messaging, imaging, and themes to achieve targeting.
Group III: Standard of CareActive Control1 Intervention
No study-specific intervention strategies (as outlined above) will be implemented in control counties at the time of the study period. Any ongoing and/or pre-existing efforts within the scope of the project's outcomes will continue as it would have i.e. a health department operating a health fair.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Health Communication
2019
N/A
~1010

Find a Location

Who is running the clinical trial?

Marc KiviniemiLead Sponsor
National Institute on Minority Health and Health Disparities (NIMHD)NIH
417 Previous Clinical Trials
1,368,599 Total Patients Enrolled
Marc T. Kiviniemi, PhDPrincipal InvestigatorUniversity of Kentucky
~1500 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top